AstraZeneca PLC (AZN)vsPhibro Animal Health Corporation (PAHC)
AZN
AstraZeneca PLC
$168.37
-2.99%
HEALTHCARE · Cap: $257.57B
PAHC
Phibro Animal Health Corporation
$34.10
-2.99%
HEALTHCARE · Cap: $1.43B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3942% more annual revenue ($61.37B vs $1.52B). AZN leads profitability with a 17.0% profit margin vs 6.6%. AZN appears more attractively valued with a PEG of 1.19. PAHC earns a higher WallStSmart Score of 63/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PAHC
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$168.37
$27.44 discount
Margin of Safety
-9.6%
Fair Value
$46.99
Current Price
$34.10
$12.89 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Earnings expanding 24.6% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
4.8% revenue growth
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : PAHC
The strongest argument for PAHC centers on Return on Equity, P/E Ratio, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : PAHC
The primary concerns for PAHC are PEG Ratio, Revenue Growth, Market Cap. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while PAHC is a value play — different risk/reward profiles.
PAHC carries more volatility with a beta of 0.47 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
PAHC scores higher overall (63/100 vs 60/100). AZN offers better value entry with a 15.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Phibro Animal Health Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?